PROCEDYTE: An Open, Prospective, Multicentre Clinical Trial With Historic Control to Determine Efficacy and Safety of Depocyte Administration (Liposomal Cytarabine) as Prophylaxis of Neuromeningeal Infiltration of Patients Between 16 and 30 Years Old With Standard Risk Acute Lymphoblastic Leukemia (ALL).

Trial Profile

PROCEDYTE: An Open, Prospective, Multicentre Clinical Trial With Historic Control to Determine Efficacy and Safety of Depocyte Administration (Liposomal Cytarabine) as Prophylaxis of Neuromeningeal Infiltration of Patients Between 16 and 30 Years Old With Standard Risk Acute Lymphoblastic Leukemia (ALL).

Discontinued
Phase of Trial: Phase III

Latest Information Update: 19 Nov 2013

At a glance

  • Drugs Cytarabine (Primary) ; Antineoplastics
  • Indications Acute lymphoblastic leukaemia; Cancer metastases
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms PROCEDYTE
  • Most Recent Events

    • 07 Nov 2012 Primary drug identified.
    • 31 Jul 2012 Status changed from recruiting to discontinued as reported by European clinical Trials database.
    • 16 Sep 2011 Planned end date changed from 1 Dec 2011 to 1 Dec 2012 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top